Why ImmunityBio Stock Is Trading Higher Thursday
Why ImmunityBio Stock Is Trading Higher Thursday
ImmunityBio, Inc. (NASDAQ:IBRX) shares are moving higher Thursday after the company announced insurance coverage of ANKTIVA across multiple states.
ImmunityBio，Inc.（納斯達克：IBRX）股價在週四上漲，原因是該公司宣佈其ANKTIVA已覆蓋多個州的保險業。
The Details: ANKTIVA is a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments.
詳情：ANKTIVA是一種免疫治療，用於治療非肌肉侵襲性膀胱癌，對其他特定治療方法無反應。
The immunotherapy received FDA approval less than two months ago and the first doses of ANKTIVA have now been administered to patients located across the United States.
該免疫治療獲得FDA批准還不到兩個月，第一批ANKTIVA劑量現已分佈在美國各地的患者身上。
"In addition to its unique mechanism of action, ANKTIVA can be readily administered by urologists in their own offices and clinics enabling more patients to receive it in familiar settings from their own providers," said Richard Adcock, CEO of ImmunityBio.
ImmunityBio的首席執行官Richard Adcock表示：“除了其獨特的作用機制外，ANKTIVA可以被泌尿科醫生在他們自己的辦公室和診所裏方便地進行管理，讓更多的患者從自己的提供商那裏得到治療。”
FDA approval was based on a clinical trial involving 77 patients with a complete response rate of 62%.
FDA批准是基於77名患者的臨床試驗，在其中完全緩解率達到了62%。
Related Link: 19 Analysts Have This To Say About Sage Therapeutics
相關鏈接：19位分析師對Sage Therapeutics發表了這些看法
IBRX Price Action: ImmunityBio stock is trading 8.11% higher at $6.73, according to data from Benzinga Pro.
IBRX股票價格走勢：根據Benzinga Pro的數據，ImmunityBio股票價格上漲8.11％，至6.73美元。
Image: Photo via Shutterstock.
圖像:通過Shutterstock拍攝的照片。